Should You Buy Odonate Therapeutics Inc (ODT) Stock on Monday?

Monday, January 10, 2022 11:02 AM | InvestorsObserver Analysts

Mentioned in this article

Should You Buy Odonate Therapeutics Inc (ODT) Stock on Monday?

Overall market sentiment has been down on Odonate Therapeutics Inc (ODT) stock lately. ODT receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Odonate Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ODT!

See Full ODT Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With ODT Stock Today?

Odonate Therapeutics Inc (ODT) stock is higher by 5.5% while the S&P 500 is down -1.79% as of 10:44 AM on Monday, Jan 10. ODT is higher by $0.06 from the previous closing price of $1.09 on volume of 336,554 shares. Over the past year the S&P 500 is higher by 20.88% while ODT is down -94.36%. ODT lost -$2.72 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Odonate Therapeutics Inc click here.

More About Odonate Therapeutics Inc

Odonate Therapeutics Inc is a US-based pharmaceutical company that is engaged in the development of therapeutics which improves and extends the lives of patients with cancer. The company mainly focuses on the development of tesetaxel, a novel chemotherapy agent that belongs to a class of drugs, taxanes, which are widely used in the treatment of cancer including breast cancer. The key product of the company is Tesetaxel which is chemotherapy for oral administration with a low pill burden for various types of cancers. Click Here to get the full Stock Report for Odonate Therapeutics Inc stock.